Lundbeck is one of the first pharmaceutical companies to leverage Gefion to accelerate drug discovery and development in neurological and psychiatric disorders, it states.

“We are excited to be among the pioneers utilizing Gefion’s AI supercomputing power. The advanced computational capabilities of Gefion come with the promise of potentially allowing us to push the boundaries of tackling brain diseases and develop treatments at an unprecedented pace,” says Senior Vice President & Head of Research at Lundbeck, Tarek Samad.

Lundbeck expects that Gefion will contribute to advancing research by providing AI-driven insights into molecule discovery and drug optimization in the development of therapies. By exploring innovative avenues for molecule discovery, Lundbeck aims to identify novel and better medicines for known drug targets as well as unlocking emerging drug targets to deliver new treatment options for people living with brain disorders, including rare and specialist-treated neurological conditions. 

Related article

AI and the 2024 Nobel Prizes: A Revolutionary Moment for Life Sciences

The 2024 Nobel Prizes in Chemistry and Physics reflect the revolutionary impact of artificial intelligence (AI) on life sciences. These awards, celebrating advancements in protein design and neural networks, demonstrate how AI is transforming how we approach drug discovery, personalized medicine, and healthcare management.


AI-powered research 

Other companies are already employing Gefion for projects spanning foundational AI research, human-centric healthcare solutions, and pharmaceutical and biotech innovation, as well as initiatives within other industries. 

“As AI reshapes industries, Gefion stands at the forefront of revolutionizing research and innovation. Together with Lundbeck we can demonstrate the game-changing potential of AI supercomputing in tackling some of the world’s most urgent healthcare challenges,” says Nadia Carlsten, CEO of the Danish Centre for AI Innovation (DCAI).

“Working together with DCAI marks an important step towards transforming brain disease research by employing AI. Providing our researchers with access to Gefion and the state-of-the-art software stack opens the opportunity to leverage the fast-evolving development of AI-driven analysis and large-scale simulations. This supports our strategy to harness the power of AI for the benefit of our patients,” says Senior Vice President of Global IT at Lundbeck, Claus Thomsen.